A 58-year-old woman has died of a rare neurological condition. The cause of death? Being injected with hormones taken from a corpse.
A woman in the U.S. has died from severe neurological symptoms that were caused by an abnormal protein — which she was unknowingly injected with nearly 50 years earlier.
Having shown no neurological symptoms in the decades since the injection, the 58-year-old recently began experiencing tremors and changes in her ability to balance while walking. In the following weeks, she developed urinary incontinence, difficulty speaking and abnormal breathing. After being admitted to hospital, she entered a coma and later died, according to a case report published May 14 in the journal Emerging Infectious Diseases.
A follow-up MRI scan while she was in hospital revealed damage to her brain, and further testing showed positive results for an abnormal protein called a prion.
Prions are found in cell membranes, the wall that surrounds every one of our cells, and are thought to be one of the molecules involved in cellular communication and other interactions.
Though prions can exist safely in the body, when these proteins accumulate in the brain they can cause surrounding proteins to contort and "misfold," damaging nerve cells. Infection with an abnormally 'folded' prion from an external source – like eating contaminated meat, as in the case of 'mad cow' disease – can also spark a chain of misfolding in the body.
The brain damage caused by prion diseases is always fatal, with most patients dying within one year of first developing symptoms, according to Mayo Clinic.
In this case, the woman was diagnosed with Creutzfeldt-Jakob Disease (CJD), an extremely rare and fatal brain wasting disease caused by prions.
Related: Here's how dangerous, deadly prions spread to the brain
It is thought the woman was given prion-infected hormones sometime between 1971 and 1980, while receiving treatment for a condition called panhypopituitarism. People with this condition have a lack of hormones produced by the pituitary gland, the organ that secretes a range of hormones including those involved in growth and sexual development.
In the 1970s, panhypopituitarism was treated by injecting patients with human growth hormones extracted from the healthy pituitary glands of people who had died. At the time, this was common practice — as well as being used to treat pituitary conditions, hormones from cadavers were also given to women whose ovaries were not producing eggs.
However, in 1985 researchers identified the first U.S. outbreak of CJD related to treatments with cadaver-derived growth hormones. The treatment was quickly suspended, and later a synthetic alternative hormone, produced by genetic engineering, was approved by the Food and Drug Administration (FDA).
RELATED STORIES
— Alzheimer's comes in at least 5 distinct forms, study reveals
— Shingles vaccine may directly guard against dementia, study hints
— 13 proteins tied to brain aging seem to spike at ages 57, 70 and 78
So far, 0.4% of those treated in the U.S with growth hormones taken from the organs of deceased individuals have gone on to develop CJD. How these hormones were infected with prions is still unknown, and scientists cannot yet explain why there is such a long latency period between the infection and the symptoms arising.
There is currently no treatment available to those with CJD, or any other form of prion disease. However, ongoing research projects seek to uncover treatments for the conditions.
The researchers involved in the recent case study said that while the number of people developing CJD as a result of growth hormone treatment has slowed over the years, it is still possible that new cases will arise.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
JUST PUBLISHED: Audrey Kuhn's Poetic Journey Through Love, Loss, and Resilience Amid Alzheimer's and Pandemic Struggles
Audrey Kuhn's poignant reflections on love, loss, and faith, published by Palmetto Publishing, illuminate resilience amid Alzheimer's and caregiving challenges. God's Voice Through the Despair Charleston, SC, Aug. 13, 2025 (GLOBE NEWSWIRE) -- God's Voice Through the Despair, authored by Audrey L. Kuhn, unveils a deeply personal journey through love, loss, and faith amid the trials of Alzheimer's, a global pandemic, and the challenges of caregiving. Audrey's narrative captures her experience as a devoted caregiver for her husband, who faces the devastating effects of Alzheimer's. Over 260 days of separation due to pandemic restrictions test her resilience, forcing her to confront the emotional weight of watching her beloved partner gradually fade away. In her darkest moments, Audrey finds solace through poetry, beginning with the poignant piece 'Little Tears,' which ignites a cascade of reflections that articulate her innermost feelings of sorrow and hope. Audrey L. Kuhn's verses explore intricate themes of love, loss, and the search for meaning amid chaos. Each poem serves as a testament to her strength, revealing the beauty of nature and the spiritual lessons learned through adversity. Her words resonate with the struggles of caregiving, encapsulating vulnerability and the courage needed to face each day. As she navigates the complexities of her husband's illness, Audrey's unwavering faith becomes her guiding light, offering comfort not only to herself but also to others grappling with similar challenges. God's Voice Through the Despair culminates in a heartfelt farewell, a final expression of love that transcends the pain of separation. This collection stands as a beacon of hope for anyone enduring the trials of caregiving, loss, and the quest for divine guidance. Audrey L. Kuhn invites readers to embrace their own narratives, reminding them that even in the darkest moments, they are never truly alone. Her journey serves as a source of comfort and inspiration, affirming the indomitable power of resilience, love, and faith. God's Voice Through the Despair is available for purchase online at and About the Author: Audrey L. Kuhn, a native of Lancaster County, Pennsylvania, is the fifth of seven children from a conservative, faith-rooted family. Her writings reflect her resilient character and compassionate spirit. Inspired by the beauty of creation, her poetry explores themes of life, death, and beyond. Many of her poems have been shared at church gatherings, funerals, and in collaborative works like Poems and Harp for the Soul. Known for her heartfelt verses, Audrey's work offers comfort to those experiencing grief or loss. Her book, God's Voice Through the Despair, showcases her enduring faith and spiritual insight. Media Contact: poemsbyaudrey@ Available for interviews: Author, Audrey L. Kuhn Attachment God's Voice Through the Despair CONTACT: Leah Joseph Palmetto Publishing publicity@


The Hill
an hour ago
- The Hill
Cowboys owner Jerry Jones says he has ‘no tumors' after stage 4 cancer diagnosis
DALLAS (KNWA) — Dallas Cowboys owner and general manager Jerry Jones says he has 'no tumors' after dealing with stage 4 cancer and using an experimental trial drug. Jones, 82, said in an interview with the Dallas Morning News on Tuesday that he was diagnosed with stage 4 melanoma in 2010 and started treatment shortly after. Roughly 105,000 new melanomas are expected to be diagnosed in the U.S. this year, according to the American Cancer Society, while about 8,400 are expected to die of the skin cancer. While the exact cause of every melanoma is unknown, the Mayo Clinic says most are brought on by exposure to ultraviolet light. Areas that are often exposed to the sun, like the skin on your arms and legs, typically serve as starting points for melanoma. Over the following decade, Jones underwent two lung surgeries and two lymph node surgeries, he told the newspaper. Treating melanoma will vary based on the severity of the case and whether it has spread. Options typically include surgery and therapies like radiation, immunotherapy, and chemotherapy, the Mayo Clinic explains. Early treatment can cure most skin cancers, the Cleveland Clinic notes, but advanced cases can be fatal. A 2021 National Library of Medicine article found that the five-year survival rate for stage 4 melanoma was 29.8 percent. 'I was saved by a fabulous treatment and great doctors and a real miracle [drug] called PD-1 [therapy],' Jones said. 'I went into trials for that PD-1 and it has been one of the great medicines.' The American Cancer Society says that PD-1 therapy is a 'checkpoint protein' that helps prevent immune cells called 'T cells' from attacking normal cells. Some cancer cells, however, have enough PD-L1, a protein found on some normal and cancer cells. Inhibitors like PD-1 are meant to help a patient's 'immune system to better find and attack the cancer cells, wherever they are in the body.' They can be used to respond to several types of cancer, according to the American Cancer Society. 'I now have no tumors,' Jones said Tuesday. ESPN reported that Jones talks about undergoing cancer treatments at MD Anderson in Houston in the upcoming Netflix documentary series ' America's Team: The Gambler and His Cowboys ', but he does not reveal the details of the treatment. The docuseries discusses Jones' purchase of the Cowboys, Tom Landry's firing, Jimmy Johnson's hiring, and the rise of the 1990s Cowboys teams. Stories about Jones' life are interspersed throughout the series. The docuseries premieres on Aug. 19.


Business Wire
3 hours ago
- Business Wire
AleraCare and PURE Healthcare Announce Intent to Merge
PHOENIX & TAYLORSVILLE, Utah--(BUSINESS WIRE)-- AleraCare, a leading provider of infusion and specialty pharmacy services across the U.S., and PURE Healthcare, a leading national medical group that delivers healthcare services for individuals with complex chronic conditions such as rheumatoid arthritis, Crohn's disease, multiple sclerosis, Alzheimer's disease and other autoimmune conditions, today announced that the businesses have entered into a definitive merger agreement. Terms of the transaction were not disclosed. The proposed merger creates an unprecedented opportunity to provide high-quality patient care, improve clinical outcomes and enhance the availability of infusion services that lower the overall cost to the healthcare system overall. Founded in 2019, AleraCare's core lines of business include ambulatory infusion centers, home infusion therapy and specialty pharmacy. Administered at convenient, accessible, patient-first locations, AleraCare is focused on maintaining trusted-partner status with physicians, payors, drug distributors and pharmaceutical manufacturers. The company has rapidly expanded to over 30 ambulatory infusion centers across the country and is a provider-of-choice for infusion services to high-need and medically complex populations. Pure Healthcare, founded in 2018, is on a mission to transform the healthcare industry by making infusion therapy more affordable and accessible—while delivering a personalized, patient-centered experience. Pure specializes in treating chronic and autoimmune conditions such as Alzheimer's disease, multiple sclerosis, and rheumatoid arthritis, offering innovative, high-quality care tailored to individual needs. Its flagship offering, Pure Infusion Suites, has expanded to 43 locations across 14 states. These state-of-the-art suites prioritize patient comfort with private rooms, snacks, and entertainment, all while significantly lowering the cost of infusion services. Pure Healthcare also alleviates the administrative burden for referring providers by supporting patient authorizations and fostering strong partnerships with insurers, ensuring a seamless and efficient care journey from referral to treatment. The transaction is expected to close in the fourth quarter of 2025, and remains subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Holland & Knight is serving as legal counsel for AleraCare. Kunzler Bean & Adamson is serving as legal counsel and Cantor Fitzgerald is acting as financial advisor for PURE Healthcare. About AleraCare AleraCare is a leading provider of infusion treatments and pharmacy services for high-need and medically complex populations. The company's core lines of business include ambulatory infusion centers, home infusion therapy and specialty pharmacy. AleraCare provides care to patients in over 30 locations across six states throughout the U.S., including Arizona, California, Colorado, Idaho, New Mexico and Utah. For more information, please visit About PURE Healthcare Pure Healthcare, founded by BUILD Capital Partners in 2018, is a national medical group dedicated to reducing healthcare costs and improving outcomes for patients with complex chronic and autoimmune conditions like rheumatoid arthritis, Crohn's disease, multiple sclerosis, and Alzheimer's. As a market leader in infusion therapy, Pure Healthcare operates Pure Infusion Suites alongside specialty clinics in rheumatology and neurology, including Memory Treatment Centers and Montana Arthritis Centers. Through strategic payer partnerships, streamlined patient authorizations, and a commitment to personalized, high-quality care, Pure Healthcare delivers scalable value to patients, providers, and payers nationwide. Learn more at